Millipore and Proteome Systems Launch In-Gel Digest Kits for Protein Sample Preparation.Business Editors and Health/Medical Writers SYDNEY, Australia & BEDFORD, Mass.--(BW HealthWire)--Dec. 18, 2001 Proteome pro·te·ome n. The complete set of proteins that are produced by the genes of an organism. proteome the entire complement of proteins produced by a cell. Systems Limited and Millipore Corporation For other uses, see Millipore. Millipore Corporation (NYSE: MIL) founded in 1954, listed among the S&P 500 since the early 1990s, is an international biosciences company, known widely for its micrometer pore-size filters and tests. (NYSE NYSE See: New York Stock Exchange :MIL) announced the new Millipore Montage montage (mŏntäzh`, Fr. môNtäzh`), the art and technique of motion-picture editing in which contrasting shots or sequences are used to effect emotional or intellectual responses. (TM) In-Gel Digest Kits, the first kits introduced since the relationship between Proteome Systems and Millipore was announced earlier this year. The kits provide a convenient and reproducible method for simultaneously preparing multiple gel samples for mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. . Bill Emhiser, president of Millipore's life sciences division, noted: "These new In-Gel Digest Kits bring to proteomics what our other kits have brought to genomics: a convenient, all-in-one kit that saves time in the laboratory by increasing throughput, standardizing protocols, and ensuring reproducibility. The new kits are a real time saver - eliminating the need for researchers to source from multiple vendors, prepare their own reagents, and optimize protocols. They also increase throughput many times over the current common practice of preparing one sample at a time." Dr. Keith Williams Keith Williams (born 21 April 1958) is a British architect. Education and career He studied architecture at Kingston and Greenwich Schools of Architecture before co-founding Pawson Williams Architects in 1987. , CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Proteome Systems, said: "Our expertise in proteomics coupled with Millipore's expertise in device manufacturing and sample preparation technologies has enabled us to co-develop a product quickly, and start serving researchers doing critical protein work around the world. The reagent reagent /re·a·gent/ (re-a´jent) a substance used to produce a chemical reaction so as to detect, measure, produce, etc., other substances. re·a·gent n. manufacturing and kit assembly is taking place in our Boston facility. We are looking forward to developing with Millipore additional kits over the coming months and years." Both of the initial kits include MultiScreen(R), a low binding 96-well filtration plate, as well as all the enzymes, reagents, and disposables necessary for digesting up to 96 protein samples from one- or two-dimensional electrophoresis electrophoresis (ĭlĕk'trōfərē`sĭs): see colloid. electrophoresis Movement of electrically charged particles in a fluid under the influence of an electric field. gels. One of the kits also includes ZipTip(R) pipette pipette /pi·pette/ (pi-pet´) [Fr.] 1. a glass or transparent plastic tube used in measuring or transferring small quantities of liquid or gas. 2. to dispense by means of a pipette. tips for concentrating and desalting samples providing improved MS data quality. The kits include an optimized protocol that provides data for successful database searches on 250 femtomole gel samples. Future kits are under development for use in automated instrumentation. For more information, go to www.millipore.com/montage. About Proteome Systems Proteome Systems is a leading proteomics technology and discovery company. With its technology partners, Proteome Systems has developed and commercialized a fully integrated platform, ProteomIQ(TM), which enables large-scale proteomic research. Proteome Systems is applying its platform to in-house discovery programs on cancer, infectious diseases infectious diseases: see communicable diseases. and aging. Proteome Systems is headquartered in Sydney, Australia and also has facilities in Boston. For more information on the company, see www.proteomesystems.com. About Millipore Millipore is a multinational, high technology company that provides technologies, tools and services for the development and production of new therapeutic drugs. It serves the life science research, biotechnology and pharmaceutical industries. For more information visit www.millipore.com. Millipore Forward Looking Statement Disclaimer The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. , are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, difficulties in the successful separation of the biosciences and microelectronics businesses; difficulties in the successful implementation of our restructuring activities; foreign exchange rates; increased regulatory concerns on the part of the biopharmaceutical industry; further consolidation of drug manufacturers; competitive factors such as new membrane technology; availability of raw materials or component products on a timely basis; inventory risks due to shifts in market demand; change in product mix; conditions in the economy in general; potential environmental liabilities; the inability to utilize technology in current or planned products due to overriding rights by third parties; difficulties inherent in research and development activities; and the risk factors listed from time to time in Millipore's filings with the SEC. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion